welcome’:’ - admin.ktn-uk.co.uk · establishing a uk vaccines development ... in-line digital...

KTN MMR2event, NRM York 07/3/18

WELCOME : Engagement Workshop for Medicines Manufacturing Challenge Fund R2

Sarah Goulding,

Knowledge Transfer Network

Some acronyms you’ll hear about today! •  KTN-‐ Knowledge Transfer Network

•  MMIP – Medicines Manufacturing InnovaHon Partnership

•  ISCF – Industrial Strategy Challenge Fund

•  KTP – Knowledge Transfer Partnership

KTN -‐ EES MeeHng 17/1/18

4

We need to take the opportunity to increase the amount of Medicines Manufacturing in the UK.

▪  Improved productivity through continuous processing and processing analytical technology offer opportunities

▪  New modalities (e.g., Antibody Drug Conjugates, oligonucleotides and the potential for synthetic biology toolkits)

▪  Technology improvement opportunity through use of digital manufacturing, AI and the Internet of Things to develop the next generation of pharma manufacturing and recapture manufacturing that has been offshored

Current UK position Critical mass of manufacturing in this area as well as strong academic capabilities

Airports

Major cities

Universities

API sites

Biologics sites

FD sites

Vaccine sites

Unknown

Company headquarters

Opportunities to become world leaders scale of manufacture required is reducing and product potency is increasing leading to worldwide gaps in capabilities

UK life science exports lower than those of Germany and the US – we can do better

MMIP government engagement

5

MMIP has engaged with Government/Policy engagement routes:

•  Advanced Therapies Manufacturing Taskforce

•  Industrial Strategy Challenge Fund -‐ UKRI •  Life Sciences Industrial Strategy •  -‐ Prof Sir John Bell

•  Part of £4.7bn extra funding for R+D innovation •  Builds on the UK’s world-class research base and delivers the science that

business needs to transform existing industries and create new ones

•  Accelerates commercial exploitation of the most exciting technologies the UK has to offer the world to ensure that scientific investment truly delivers economic impact, jobs and growth right across the country

•  Programmes delivered by the fund will be industry-led and powered by multi-disciplinary research and business-academic collaboration

•  Delivered by Innovate UK and Research Councils UK, and eventually UK Research and Innovation, the single voice for the UK’s research and innovation landscape

Industrial Strategy Challenge Fund (ISCF)

UK Research and Innovation

Wave 1 – Medicines Manufacturing ISCF Competitions 2017 Fund Applications Status

Digital Health Technology Catalyst round 1 £8m Closed Awarded

Medicines manufacturing round 1: challenge fund £15m Closed Awarded

Viral vector production for cell and gene therapies £16m Closed Awarded

Establishing UK medicines manufacturing innovation centre £13m Closed Awarded

Establishing UK treatment centres for advanced therapies £30m Closed Conditional award

Establishing a UK vaccines development & manufacturing centre £66m Closed Assessment

ISCF Competitions 2018

Digital Health Technology Catalyst round 2 £8m Opens 15/02/18

Medicines manufacturing round 2: challenge fund £10m Opens 12/03/18

Digital Health Technology Catalyst round 3 TBC To open autumn ‘18


ISCF Wave 2 and 3

Successful ISCF Wave 2 proposals - TBA very soon ISCF Wave 3 - open for Expressions of interest: visit here


1. Overview of Round 1 Projects 2. Round 2 Competition Scope details Dr Nick Medcalf Interim Challenge Director - Medicines Manufacturing [email protected]


InvesHng in science, research & innovaHon

Upgrading infrastructure

Improving procurement

Delivering affordable energy & clean

growth

Driving growth across the whole

country

Developing skills SupporHng businesses to start & grow

Encouraging trade & inward investment

CulHvaHng world-‐leading sectors

CreaHng the right local insHtuHons


Investing in science, research and innovation ��We must become a more innovative economy and do more to commercialise our world leading science base to drive growth across the UK

Industrial Strategy Challenge Fund§ Industry-led and powered by multi-disciplinary research and business academic collaboration§ Develop UK industries that are fit for the future, driving progress in technologies where the UK can become a world-leader in research and commercialisation


Engagement workshops

Announced first challenges

in March

Industrial Strategy consultation

closed


Second wave Challenges

Competitions for for first wave of challenges

Scaling first wave of challenges

Engagement about future years

Second wave competitions for FY18/19

First Wave of funding

Announced


ISCF Wave 1 Challenges

Medicines manufacturing technologies

Batteries for clean and flexible energy storage

Robots for a safer world

Self-driving vehicles

Manufacturing and materials of the future

Satellites and space technology


ISCF Medicines Manufacturing Challenge

Medicines Manufacturing Collaborative R&D

£25m

Advanced Therapies Treatment Centres

£30m

Cell & Gene Therapy Manufacturing Centre

£12m

Medicines Manufacturing Innovation Centre

£13m

Vaccines Development & Manufacturing Centre

£66m

£146m to develop first-of-a-kind technologies for the manufacture of medicines to accelerate patient access to new drugs and treatments


ISCF Medicines Manufacturing Challenge

Advanced Therapies Treatment Centres

£30m

Cell & Gene Therapy Manufacturing Centre

£12m

Medicines Manufacturing Innovation Centre

£13m

Vaccines Development & Manufacturing Centre

£66m

£146m to develop first-of-a-kind technologies for the manufacture of medicines to accelerate patient access to new drugs and treatments

Medicines Manufacturing Collaborative R&D

£25m


Overview of Round 1 Projects

Feasibility Studies (£1m)

Collaborative R&D (£14m)


Medicines Manufacturing Round 1 Feasibility Studies These proposals have succeeded in the assessment stage. Subject to grant offer and conditions. 1.  OXFORD MESTAR LIMITED, SEE-THROUGH SCIENTIFIC LIMITED 2.  BIOPHARMA PROCESS SYSTEMS LIMITED, De Montfort University

ONCOLYTIKA LTD 3.  CHAIN BIOTECHNOLOGY LIMITED, PORTON BIOPHARMA LIMITED SCITECH

ENGINEERING LTD 4.  BIOMOTI LIMITED, CENTRE FOR PROCESS INNOVATION LIMITED

PHARMIDEX PHARMACEUTICAL SERVICES LIMITED 5.  ANGLO BIOPHARMA LIMITED, ABSOLUTE ANTIBODY LIMITED University of

Reading 6.  N4 PHARMA UK LIMITED, MEDIMMUNE LIMITED


Medicines Manufacturing Round 1 Feasibility Studies These proposals have succeeded in the assessment stage. Subject to grant offer and conditions. 7.  ADDED SCIENTIFIC LIMITED, XAARJET LIMITED 8.  TECEXEC LIMITED 9.  RENEURON LIMITED, National Institute for Biological Standards and Control 10.  BIOTOOLOMICS LIMITED


Medicines Manufacturing Round 1 Feasibility Studies These proposals have succeeded in the assessment stage. Subject to grant offer and conditions. 1.  In-line digital holographic microscopy for automated QC and process control 2.  Formulation accelerated freeze-drying by reduced vapour flow resistance (micro-

collapse) 3.  Anaerobic bacterial spore therapeutics and their manufacture 4.  Paclitaxel-loaded biodegradable microparticle production optimised on a

microfluidics platform 5.  mAb manufacturing for future subunit vaccine platform 6.  Nanoparticles for the delivery of therapeutic Papilloma Virus (HPV) nucleic acid

vaccines


Medicines Manufacturing Round 1 Feasibility Studies These proposals have succeeded in the assessment stage. Subject to grant offer and conditions.

7.  Inkjet printing for pharmaceutical applications 8.  Active and passive Ingredient wet Milling (AIM) 9.  Single cell transcriptome profiling for advanced cell therapy manufacturing 10.  Very efficient platform purification process for gene therapy medicines


Medicines Manufacturing Round 1 CR&D These proposals have succeeded in the assessment stage. Subject to grant offer and conditions. 1.  LABXERO LIMITED, CELL THERAPY CATAPULT LIMITED CELLULAR THERAPEUTICS LTD

University of Cambridge 2.  TERAVIEW LIMITED, GLAXOSMITHKLINE PLC HUXLEY BERTRAM ENGINEERING LIMITED

University of Cambridge 3.  REXGENERO LIMITED, CELL AND GENE THERAPY CATAPULT THERMO ELECTRON

LIMITED TRAKCEL LIMITED 4.  AUTOLUS LIMITED, University College London 5.  SYNPROMICS LTD, LONZA BIOLOGICS PLC 6.  CAMENA BIOSCIENCE LIMITED, CENTRE FOR PROCESS INNOVATION LIMITED,

GLAXOSMITHKLINE PLC


These proposals have succeeded in the assessment stage. Subject to grant offer and conditions.

7.  IPSEN BIOPHARM LIMITED, CENTRE FOR PROCESS INNOVATION LIMITED TOUCHLIGHT GENETICS LIMITED

8.  ARC TRINOVA LIMITED, University of Nottingham 9.  MEIRAGTX UK II LIMITED, SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED

TOUCHLIGHT GENETICS LIMITED 10.  RENEURON GROUP PLC, CELL THERAPY CATAPULT LIMITED ROSLIN CELL THERAPIES

LIMITED University College London 11.  PHICO THERAPEUTICS LIMITED, GE HEALTHCARE UK LIMITED THE CLINICAL TRIAL

COMPANY LTD https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/672700/Medicines_Manufacturing_Round_1_-_CRD_-_Competition_Results.pdf

Medicines Manufacturing Round 1 CR&D


These proposals have succeeded in the assessment stage. Subject to grant offer and conditions. 1.  Acoustic enhancement of cell separation 2.  New rapid and non-destructive test instrument for predicting tablet efficacy and performance 3.  Automated needle-to-needle supply chain management and extended shelf life 4.  Innovative and scalable viral vector processes 5.  Development of a novel inducible expression system for the manufacture of therapeutic proteins

from CHO cells 6.  Rapid Metabolite Analyser for Medicines Manufacture



These proposals have succeeded in the assessment stage. Subject to grant offer and conditions. 7.  Novel production process for a highly potent recombinant protein using cell free expression 8.  Flexible modular manufacturing technology platform for intensification of drug substance

manufacture 9.  Development and implementation of next-generation commercial gene therapy manufacturing

platform 10.  Multi-donor allogeneic human retinal progenitor cell therapy (hRPC) 4sight 11.  Development of Manufacturing Process of Engineered-Phage for IV administration in

P.aeruginosa infections



Round 2 Competition Scope details


Medicines Manufacturing Round 2 •  Round 2 up to £10m for innovation projects in medicines

manufacturing •  Opens: March 12th 2018 •  Application deadline: May 9th 2018 12:00 p.m. •  Leader must be UK-based business •  All projects must be business-led and involve at least one SME


Medicines Manufacturing Round 2 •  Your project must aim to improve the productivity, competitiveness

and growth for at least one UK SME involved in the project •  You must start your projects by September 1st 2018 •  You must complete before April 2021 (note Feasibility Project

timeline, next slide) i.e. duration between 6 and 30 months •  Your project’s total costs should be between £50,000 and £1.5

million. •  For all research organisations, the total level of project participation

is set at a maximum of 30% of total eligible project costs


Medicines Manufacturing Round 2 Two streams:

•  Feasibility studies •  Industrial research and experimental development

1. Feasibility studies: •  Total project costs must range in size from £50,000 to £100,000 •  Projects can be from a single SME or you can work with other

businesses or research organisations •  You must complete your project within 12 months


Medicines Manufacturing Round 2 1.  Feasibility studies: Exploration and evaluation of the commercial potential of an early-stage concept. Your project must deliver:

•  Assessment of the business opportunity •  Validation of the initial concept •  Potential conceptualisation •  Scoping for further development


Medicines Manufacturing Round 2 2. Industrial research and experimental development: The development of new and innovative solutions to medicines manufacturing challenges. Your proposal must demonstrate:

•  The current challenge and value proposition •  A clear understanding of the market potential, routes to market

and commercialisation strategies


Medicines Manufacturing Round 2 2. Industrial research and experimental development:

•  Total project costs up to £1.5 million (we can consider projects outside this range but you must contact us at least 10 days before the submission deadline to discuss)

•  Projects must be collaborative. •  The lead organisation must claim funding through this

competition. If the project is collaborative, at least one other organisation in the consortium must also claim funding.



•  Projects must include a site that holds a full manufacturing and importation authorisation (MIA licence) or a manufacture of investigational medicinal products (MIA IMP) licence in the UK for the manufacture of the appropriate type of medicine

•  You must complete your project between 12 and 30 months from the start date

•  Any one business may lead on one application and partner in a further 2 applications.



•  RTOs cannot lead on an application but can be a collaborator in any number of applications.

•  Academics cannot lead on an application but can be a collaborator in any number of applications.


Medicines Manufacturing Round 2 Competition aim: Stimulate the development and implementation of innovative methods/technologies to improve the manufacture of novel medicines for human use.

‘Novel’ medicines are those that have not yet been commercially launched on the market but may have been applied as part of clinical trials or under exemptions from the UK Human Medicines Regulations.

Your proposals can include, but are not limited to, approaches that have the potential to deliver:


Medicines Manufacturing Round 2 Competition aim: • In each case there must be reason to expect an improvement in excess of 25%. Small incremental improvements will be deemed to be outside scope. • ‘Novel’ medicines are those that have not yet been commercially launched on the market but may have been applied as part of clinical trials or under exemptions from the UK Human Medicines Regulations.


Medicines Manufacturing Round 2

•  Improved commercially viable manufacturing processes •  Methods for the reliable and robust scale-up of production of

novel medicines •  Increased yield of active ingredient •  Lower cost of production and goods

In each case there must be reason to expect an improvement in excess of 25%. Small incremental improvements will be deemed to be outside scope.


Medicines Manufacturing Round 2 In this competition medicines that are in scope and can be used as exemplar products are limited to:

•  Advanced therapy medicinal products •  Natural product medicines •  Nucleic acid-based drugs •  Prophylactic vaccines •  Protein or peptide biopharmaceuticals •  Small molecular weight pharmaceuticals •  Virus and phage therapeutics


Medicines Manufacturing Round 2 We are particularly encouraging applications that address:

•  In-process monitoring, control and release testing •  Maintaining product-critical quality parameters such as purity,

potency and viability •  Formulation processes •  Packaging and storage processes •  Product characterisation •  Process challenges for increasing the scale of production


Medicines Manufacturing Round 2 •  Process development and effective site-to-site transfer for novel

medicines •  Transfer of technology from small-scale manufacturing to a good

manufacturing practice (GMP) manufacturing facility •  Lowering of the cost of goods •  Increase in yield of active ingredient •  Increase in speed of production cycle •  Methods to increase the flexibility of established manufacturing

facilities •  Adaptation of processes from batch to continuous production


Medicines Manufacturing Round 2 In this competition we will not fund: • Small incremental improvements to an existing process • Medicines discovery • Manufacturing process innovation using a non-human medicine as the product • Manufacturing process innovation using a marketed medicine as the product • Product or prototype development where the main innovation, challenge or risk is not in the manufacturing process • Projects that apply existing and well-known manufacturing processes, without significant innovation challenges, to develop a new product • Manufacturing process innovation that does not apply to the list of medicines detailed in the scope


Medicines Manufacturing Round 2 Projects should deliver solutions in the following themes: •  Improved commercially viable manufacturing processes •  Methods for the reliable and robust scale-up of production of novel

medicines •  Increased yield of active ingredient •  Lower cost of production and goods


Medicines Manufacturing Round 2 For feasibility studies and industrial research projects, you could get funding for your eligible project costs of: •  Up to 70% if you are a micro or small business •  Up to 60% if you are a medium-sized business •  Up to 50% if you are a large business


Medicines Manufacturing Round 2 For experimental development projects which are nearer to market, you could get funding for your eligible project costs of: •  Up to 45% if you are a micro or small business •  Up to 35% if you are a medium-sized business •  Up to 25% if you are a large business


Questions already asked •  1. Does the actual named licence holder (IMP) at an institute have to be named on the

application, or is it sufficient the institute holds an IMP licence? •  The named licence holder does not have to be named on the application but the name of the

organisation and the site must be named in the application. •  2. Can the collaborator be applying for an IMP licence at the time of application (with any award

being conditional on this criteria being met subsequently) or must the licence be in place at the time of application submission?

•  The licence must be in place at the time of the application submission. •  3. If we wanted to work with a government backed IMP licence holder e.g. CBC NHSBT would

they be an eligible collaboration partner? •  A government backed IMP licence holder can be an eligible collaboration partner.


Points to note (from Round 1)

Project costs of up to £100,000 • If you are a micro or SME and your eligible project costs are up to £100,000, you can run the project on your own. You can also work with other businesses or research organisations.

Project costs of £100,000 or above • If your eligible project costs are more than £100,000 you must work with other organisations who are claiming grant as part of the project. At least one member of the consortium must be a micro or SME.



Do not confuse total costs with eligible costs • Please read and familiarise yourself with the Funding rules Guidance https://www.gov.uk/guidance/innovate-uk-funding-general-guidance-for-applicants#funding-rules. Do not assume that if the IFS accepts your application then all your cost calculations are correct.

RTO funding • The research organisations collaborating as part of a consortium may share up to 30% of the total eligible project costs. If your consortium contains more than one research organisation, this maximum will be shared between them.



Projects may include partners that don’t receive any funding (for example, non-UK businesses). • Their costs will count towards the total project costs but they will not count as collaborators.


Search for the competition


Competition criteria


Questions?

Dr Nick Medcalf Interim Challenge Director - Medicines Manufacturing [email protected]


Wider Funding Opportunities from Innovate UK Dr Nick Medcalf Interim Challenge Director - Medicines Manufacturing [email protected]


Additional Innovate UK funding competitions

Innovate UK Funding Competitions Fund Opens Closes

Innovation loans: manufacturing and materials readiness £10m 26//02/18 25/04/18

March 2018 sector competition: Open £15m 01/03/18 09/05/18

Support for SMEs to evaluate innovative medical technologies £1m 29/01/18 21/03/18

January 2018 sector competition: strand 1, health and life sciences & strand 2, emerging and enabling technologies (additional £12m available for KTPs)

£19m £12m

22/01/18 28/03/18

NHS Test Beds: business expression of interest £6m 26/02/18 27/03/18

Analysis for innovators round 2: brokerage £4m 05/03/18 04/04/18 For competition details and a complete and up-to-date list of Innovate UK funding opportunities visit: https://apply-for-innovation-funding.service.gov.uk/competition/search


•  Budget up to £10 million in loans to SMEs for innovative manufacturing or materials projects.

•  Manufacturing readiness applies to innovations in manufacturing systems, technologies or processes, and/or materials development, properties, integration or reuse.

•  Proposals should focus on the scale-up of recent or ongoing manufacturing process innovation and/or materials development activities.

•  The project’s aim should be to enable UK based companies to progress innovative manufacturing or materials developments to commercial readiness.

Innovation loans: manufacturing and materials readiness – Description (1)


•  Projects should last up to 5 years, of which up to 3 years can focus on research and development (R&D), and up to 2 more years to establish a clear route to commercial success. Loan repayments will be required over a further period of up to 5 years.

•  Businesses must be able to show that they:

•  can cover interest payments •  will be able to repay the loan on time

•  need public funding •  Loans of between £100,000 and £1 million are available. Projects should

last up to 5 years.

Innovation loans: manufacturing and materials readiness – Description (2)


•  To take on an innovation loan for a project you must: •  be a UK based SME •  carry out your project in the UK

•  a single business – collaborations cannot be funded in this competition •  Individuals, research organisations and large companies are not eligible.

•  Innovation loans will not be offered to: •  businesses we consider unable to afford the interest and repayments

•  businesses that have not demonstrated that they are unable to obtain finance from other sources on suitable terms

Innovation loans: manufacturing and materials readiness – Eligibility


•  We have allocated up to £10 million in this competition. •  We will offer loans of between £100,000 and £1 million. •  Innovation loans will be up to 100% of eligible project costs and will be:

•  Available for up to 3 years (the ‘availability period’) when the project is under way, but the exploitation has not yet started.

•  Extended for up to 2 years (the ‘extension period’) when the project is focused on developing the commercialisation of the product.

•  Repayable over a maximum of 5 years (the ‘repayment period’) after the availability and extension periods. Interest will be charged at the rate of 3.7% per year on outstanding amounts, payable quarterly in arrears.

Innovation loans: manufacturing and materials readiness – Funding and Project Details


Achieving manufacturing and commercial readiness. This should include:

•  capability to produce prototype products or systems at scale

•  evidence that a financeable business with significant market potential can be developed during the commercialisation phase

•  ability to market and sell the resulting products, processes or services

Manufacturing or materials innovation rather than a product innovation. Show significant late stage innovation. Show how you are working with end users in one of our priority areas:

•  manufacturing system, technology, process or business model

•  materials development, properties, integration or reuse

Innovation loans: manufacturing and materials readiness – Scope


Technology Readiness Level (TRL) 5 or higher, and/or at a Manufacturing Readiness Level (MRL) of 4 or higher, when the loan period commences.

Examples (not exhaustive):

1. Creation of new or improved manufacturing facilities

2. Development of software

3. Development of new business models

4. Materials testing

Innovation loans: manufacturing and materials readiness – Themes


•  Budget of up to £19 million in highly innovative projects with the best game changing and/or disruptive ideas or concepts.

•  Projects should aim to lead to new products, processes or services (or novel use of existing ones) believed to be significantly ahead of anything similar.

•  Any technology (including arts, design, media or creative industries) and any part of the economy.

•  Focus on commercialisation, growth or scale up as soon as possible following completion.

•  Priority is given to proposals likely to lead to growth, gains in productivity and/or access to new overseas markets through export.

March 2018 sector competition: Open - Description


•  Total costs should be between £25,000 and £1 million depending on the type of research and development (R&D) to be undertaken.

•  Project duration should be a minimum of 6 months, and a maximum of 3 years.

•  Open to UK based business of any size, project work in the UK, exploit the results in or from the UK

•  Work alone or in collaboration with others (businesses, research base or third sector)

•  Lead organisation must claim funding through this competition. If collaborative, at least one other organisation must also claim funding.

March 2018 sector competition: Open - Size


•  The percentage of costs through a grant depends on the type of research and size and type of organisation involved.

•  Projects can focus on:

•  feasibility studies (which can include market research)

•  industrial research

•  experimental development, depending on the challenge identified and proposed solution

•  A further £10 million is available to fund Knowledge Transfer Partnerships (KTPs) which is a completely separate programme. Further details can be found on the KTP website.

March 2018 sector competition: Open – Types of Project


For feasibility studies (which may include market research) and industrial research projects, you could get funding for your eligible project costs of:

•  up to 70% if you are a small business

•  up to 60% if you are a medium-sized business

•  up to 50% if you are a large business

For experimental development projects which are nearer to market, you could get funding for your eligible project costs of:

•  up to 45% if you are a small business

•  up to 35% if you are a medium-sized business

•  up to 25% if you are a large business

March 2018 sector competition: Open – Funding


We will not fund proposals that:

•  do not meet the competition scope, project costs or duration

•  do not address the size, potential for, and access to the market for the innovation

•  cannot present evidence that their idea or concept has the potential to lead to significant return on investment (ROI), positive economic impact, growth and scale-up of the business

•  have a current project funded through the Smart programme that will not have its project completion meeting before the close date for this competition

March 2018 sector competition: Open – Projects not funded


The Office for Life Sciences in partnership with Innovate UK is to invest up to £1 million to support developers of innovative medicines, medical devices, diagnostics and regulated digital technology to evaluate their product in a real world clinical setting.

• Support for small and medium-sized enterprises (SMEs) to generate an evidence base that will enable the evaluation of products that address NHS priorities.

• This support is intended to allow companies to collect and analyse clinical performance and cost effectiveness data within an NHS setting.

Proposals should:

• describe the innovative medicine or CE-marked device

• include any current up to date evidence of the product’s clinical performance and cost effectiveness

• demonstrate how the product meets the priority needs defined in next steps on the NHS 5 year forward view, and how it is expected to deliver significant cost savings, health gains or beneficial service impacts, if quickly adopted across NHS England

• provide evidence that you are working with appropriate stakeholders including NICE, NHS England, NIHR and AHSNs.

Support for SMEs to evaluate innovative medical technologies (1)


•  include the development or implementation of plans for data collection within the NHS •  outline how studies will generate data on the costs and benefits of a product, allowing

evaluation by NICE •  All projects must be business led. •  Collaborative partners are permitted but not required. Only the lead partner can claim

grant. Project size •  Competition closes 21 March 2018 12:00pm •  Total project costs must range in size from £50,000 to £250,000. •  Projects must start by 1 June 2018 and be completed by the end of March 2019.

Support for SMEs to evaluate innovative medical technologies (2)


Innovate UK will invest up to £19 million in innovation projects that inspire new products, processes and services. These should address challenges in emerging and enabling technologies. • The aim of this competition is to help UK businesses broaden their innovation activities, disrupt existing markets and find new revenue sources.

• A further £12 million is available to fund Knowledge Transfer Partnerships (KTPs).

Projects must show significant innovation in one of our 4 priority areas: • Emerging technologies (biofilms, energy harvesting, graphene, new imaging technologies).

• Digital

• Enabling capabilities, including electronics, sensors and photonics (ESP), robotics and autonomous systems (RAS), creative economy and design

• Space applications

• Competition closes 28 March 2018 12:00pm

January 2018 sector competition – Description (1)


•  This competition has 2 strands. This is the emerging and enabling strand. The other strand is health and life sciences.

•  If you are a business, you can carry out the project on your own or you can collaborate with others. A business or research and technology organisation (RTO) must lead the project. If your project size falls outside of our scope, contact us before you apply.

•  Project size •  Your project’s total costs should be between £35,000 and £2 million.

Projects should last between 3 months and 3 years.

January 2018 sector competition – Description (2)


•  Innovate UK is to invest up to £4.5 million on behalf of the Office for Life Sciences.

•  This is in projects that integrate new product and service innovations. •  These projects must produce significant health improvements at the

same or less cost than existing practice. •  An additional £1.5 million is available from NHS England. This is

specifically for projects that integrate digital approaches to self-management education and support for people with type 2 diabetes.

•  This is the first stage of the competition and is calling for expressions of interest (EoI).

NHS Test Beds: business expression of interest – Description (1)


•  By entering you state that you have a market-ready digital product and are willing to partner with an NHS organisation or partnership.

•  The EoI part of this competition has 2 strands. This is the business strand. The other strand is for NHS organisations or partnerships.

•  To apply you must be a business with a digital product that addresses a clearly defined health and care challenge that is in line with the national NHS and life sciences priorities.

•  If your proposal is selected, you will be invited to attend a collaboration workshop between 9 and 13 April 2018 where consortia will be formed. If you establish a consortium, you will be requested to submit a detailed application to the full Test Beds competition.

NHS Test Beds: business expression of interest – Description (2)


UK businesses can apply for a share of up to £4 million to work on analysis and measurement problems to address their productivity issues by working with the best scientists and research facilities. Funding partners:

•  the National Physical Laboratory (NPL) •  the National Measurement Laboratory at LGC (formerly known as

the Laboratory of the Government Chemist) •  the National Engineering Laboratory (NEL) •  the Science and Technology Facilities Council (STFC)

Analysis for innovators round 2: brokerage (1)


•  Describe the problem you are aiming to solve. We will only consider problems that:

•  are related to the measurement or analysis of some quantities or properties of an existing process, product or service

•  are not effectively solvable by simple ‘off the shelf’ methods or techniques

•  Provide an outline and quantify some of the perceived benefits of the problem being solved.

•  You should not attempt to propose how the problem should be solved.

•  Outline any methods and attempts that you have previously tried to address the problem.

•  Analysis problems should not be data processing but might involve the development of new algorithms or approaches to analysing measurement data as part of a measurement system.

•  We are looking to address a portfolio of problem types, across a variety of technologies, markets and sectors.



•  Project costs could be up to £250,000. •  Consultancy sessions will start from May 2018 and follow-on projects

will typically last up to 12 months. •  Competition opens: Monday 5 March 2018 •  Competition closes: Wednesday 4 April 2018 12:00pm •  Aim: Match the best UK scientists and cutting-edge facilities with

companies that have analysis or measurement problems. •  Your application should describe the problem and estimate the value

to your company of solving it.



•  Successful applicants will receive free consultancy. They will also receive information about options for funding projects to work on solutions with the relevant funding partner organisations.

•  This is the first stage of a 2-stage competition.

•  The second stage, which includes funding options from the 4 funding partners or Innovate UK, will be described in more detail at the roadshow and launch events.



We will not consider problems that:

• are not measurement or analysis problems

• we consider to be addressable with easily available methods, such as those that don’t require any innovative or cutting-edge science or facilities

• are not related to a company’s existing processes, products or services



Questions?

Dr Nick Medcalf Interim Challenge Director - Medicines Manufacturing [email protected]

The Future. Faster

As a network partner of Innovate UK, KTN combines experHse in all sectors with the ability to cross boundaries

ConnecHng with KTN can lead to potenHal collaboraHons, horizon-‐expanding events and innovaHon insights relevant to your needs

ConnecOng people to drive innovaOon

— Find experHse — Find markets — Find finance

How it works

— A[end events

— Receive expert advice & insights

— Get help with crossing sectors

— IntroducHons to new collaboraHons

AcOviOes and projects

From roadmaps to steering groups from influencing government policy to special interest groups, our acHviHes and projects evolve constantly to reflect industry needs

KTN and Knowledge Transfer Partnerships Sarah Goulding, KTN

The Future. Faster

As a network partner of Innovate UK, KTN combines experHse in all sectors with the ability to cross boundaries

ConnecHng with KTN can lead to potenHal collaboraHons, horizon-‐expanding events and innovaHon insights relevant to your needs

ConnecOng people to drive innovaOon

— Find experHse — Find markets — Find finance

How it works

— A[end events

— Receive expert advice & insights

— Get help with crossing sectors

— IntroducHons to new collaboraHons

AcOviOes and projects

From roadmaps to steering groups from influencing government policy to special interest groups, our acHviHes and projects evolve constantly to reflect industry needs

What Are KTPs?

1.  KTP Programme running more than 40 years 2.  Company driven, strategically important project 3.  Partnership with an academic team 4.  Employ an “Associate”, a recent graduate often with a Master’s or

PhD 5.  Deliver new capabilities and a sector leading innovative product/

process 6.  Around 100 active Partnerships in Scotland (~700 across UK) 7.  Growing - £30million of ADDITIONAL funding is allocated to KTP

for the current year

Idea

Capability

Product/ Service

Capability

Opportunity

InnovaHon

Where KTP fits

KTP KTP

ExtracHng value from universiHes to create growth

Knowledge Intensive challenges

Key Characteristics of KTP

Structured project management

Project with high impact, innovation and challenge, coherently planned

The Associate is employed by the university partner, recruited jointly

Project and associate located at business premises with joint business & academic supervision

KB Supervisor spends approx. half a day per week at the business premises (knowledge exchange)

Project length of between 12 & 36 months

More competitive, wealth creating business

Well developed ‘manager of future’

Impact Research, Teaching, Papers, Placements etc

Transfer & ‘embedding’ of knowledge

Vital Knowledge

Support partnership fully

University/Research Organisation Has it got the missing knowledge?

Can it benefit from the project?

Business Affordability

Strategic + Net Profit Impact Can it develop the graduate?

Associate (Graduate) What skills are needed?

Will they be stretched and developed?

Business has strategic needs to address

Company-based project, strategically important, vital knowledge missing.

KTP Essential Features

Company Benefits •  Company gains a strategic capability

•  Enables the achievement of strategic goals

•  Delivers significant disruption in their market

•  High Impact changes to

–  Profitability

–  Innovation Culture

–  Company Resilience

–  In house capabilities

•  Increase in annual profit before tax (post KTP) £1,012,000 •  Investment in plant and machinery £194,000 •  New jobs created 3

•  Business staff trained 31 •  Investment in other R&D activity £265,000

•  Plans for further collaboration 86% •  Improved business performance/innovation culture 90% •  Anticipated increase in annual exports £967,000

Data from 2013-14 Report

University Benefits

•  It’s a source of income

•  It’s often enjoyed by the academics adding some variety

•  It’s a source of new teaching materials for courses

•  It creates opportunity to publish

•  It creates great Kudos for the University, great case study material

•  Extends the reach of their research activities

•  Benefits the many institutes and SIG’s they cultivate.

•  Engages their local business communities

The Associate

Recently Qualified with:

•  First degree ~ 85% hold 1st or 2(i)

•  Higher degree ~ 65%

•  Average age 29 years

•  All disciplines

•  From any university world wide

1. Graduate Salary (Pay £18-‐38k pa) £27 -‐ £45k

2. Graduate Development, Travel, Equipment ~ £6k

3. Access to university experHse and faciliHes ~ £30k

Total Package worth £60 -‐ £85k

SME 67% Grant Support, Cost to Company £20 -‐ £28k

Large Company 50% Grant Support, Cost to Company £30 -‐ £42k

Balance funded by KTP Sponsors via Innovate UK

Typical Costs Per Project Year

Business Benefits

•  Increase in annual profit before tax (post KTP) £1,012,000 •  Investment in plant and machinery £194,000 •  New jobs created 3 •  Business staff trained 31 •  Investment in other R&D acHvity £265,000 •  Plans for further collaboraHon 86% •  Improved business performance/ innovaHon culture 90% •  AnHcipated increase in annual exports £967,000 Data from 2013-‐14 Report

Benefits per Associate project (averages)

KTP Advisers

Knowledge Transfer Adviser MapContact an adviser closest to the business [email protected]@KTNUK

Gerry Black07841 051534

GLASGOW

Ian HeywoodABERDEEN

Jim Berryman07860 863651EDINBURGH

Ian Blakemore07753 138299STOCKTON ON TEES

John Clayton07860 863635CONSETT

Trevor Gregory07860 863644ILKLEY

Fiona Nightingale07823 324342

LYMMPhilippa Ryan07860 863649NOTTINGHAMKamran Hussein07834 150492LEICESTERJody Chaterjee07860 863646CAMBRIDGEJan Stringer07860 863634COLCHESTERTerry Corner07860 863645SEVENOAKS

Anne Hartnell07912 875552

WOKINGHAM

Joel Ferguson07739 338681

BALLYCAREKen Frame

07860 863639BANGOR

Andrew Kenney07860 863636

MORECAMBE

Russ Bromley07889 829322

STOKE

Mark Matchett 07583 075148

WALSALLJose Freedman01926 490100

WARWICKHoward Nicolls

07711 915353CARDIFF

Gerry O’Hagan07860 863638MARLOW

Stephen Woodhouse07860 863652

SALISBURY Andy Treen07584 705411

EXETER

Susan SuttleLIVERPOOL

Mick Card07770 418790

CHESTER

Get in touch •  [email protected]

•  Marcel Kuiper •  Terry O’Neill •  Alexander Henzing

welcome’:’ - admin.ktn-uk.co.uk · establishing a uk vaccines development ... in-line digital...

Documents